CL075
CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively[1][2][3].
Product Specifications
CAS Number
256922-53-9
Product Name Alternative
3M002
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cl075.html
Concentration
10mM
Purity
99.25
Solubility
DMSO : 22 mg/mL (ultrasonic; warming)
Smiles
NC1=NC2=CC=CC=C2C(S3)=C1N=C3CCC
Molecular Formula
C13H13N3S
Molecular Weight
243.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine. 2014 Sep 29;32 (43) :5593-9.|[2]Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185 (1) :738-47.|[3]Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J Leukoc Biol. 2015 Jun;97 (6) :1081-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TLR8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
